New Drug Approvals

JANUARY 31, 2024

BLZ945 decreases the growth of malignant cells in the mouse mammary tumor virus-driven polyomavirus middle T antigen (MMTV-PyMT) model of mammary carcinogenesis. BLZ945 attenuates the turnover rate of TAMs while increasing the number of CD8+ T cells that infiltrate cervical and breast carcinomas.

Small Molecule 52

Small Molecule Virus Treatment Disease 52

The Pharma Data

OCTOBER 14, 2020

The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. About TNX-1800.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

SEPTEMBER 12, 2020

The pivotal trial is event-based and there are many variables that will ultimately impact read-out timing. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Vaccine 52

Vaccine Trials Clinical Trials Small Molecule 52

The Pharma Data

AUGUST 20, 2020

We are proud to share our findings with the scientific community as we continue our work to deliver a safe and effective vaccine to combat this devastating virus,” said Kathrin U. Systemic events after administration of BNT162b2 were milder than those with BNT162b1. No severe systemic events were reported by older BNT162b2 recipients.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

SEPTEMBER 9, 2020

BNT162b2 encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S), which is the target of virus neutralizing antibodies. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. About the Phase 2/3 Study.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

MAY 7, 2021

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer- BioNTech COVID-19 Vaccine. anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

DECEMBER 5, 2020

About Syros Pharmaceuticals Syros is redefining the power of small molecules to control the expression of genes. The trial will also evaluate the triplet as a salvage therapy in patients who don’t respond to venetoclax and azacitidine. Syros expects to initiate the Phase 2 trial in the second half of 2021. Posted: December 2020.

Clinical Trials 52

Clinical Trials Trials Small Molecule Treatment 52

The Pharma Data

JULY 21, 2021

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine. Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS online at [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

SEPTEMBER 9, 2020

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease. The study is an event-driven trial. Argentina and Brazil.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

MAY 6, 2021

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine. anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 11, 2020

The study also will explore prevention of infection by SARS-CoV-2, the virus that causes COVID-19. Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer BioNTech COVID-19 Vaccine.

Vaccine 52

Vaccine Clinical Trials Trials Licensing 52

The Pharma Data

NOVEMBER 9, 2021

In a new study published in the journal JCI Insight, Brown University researchers describe the cellular and molecular events that explain why these groups have a higher risk of infection as well as of severe side effects and death. “This paper details a major discovery in COVID-19,” said corresponding author Dr. .

Small Molecule 52

Small Molecule Virus Molecular Biology Disease 52

Drug Target Review

JULY 7, 2023

Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them. Antibodies are proteins that guard against foreign substances that enter our bodies,such as bacteria, fungi, viruses and toxins.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

AUGUST 18, 2020

CARE will focus on three strategic pillars to achieve therapeutic breakthroughs against SARS-CoV-2 (the virus that causes COVID-19 disease) and other coronavirus threats: Drug repositioning and repurposing. Small molecule discovery. Virus-neutralizing antibody discovery. Source link.

Treatment 52

Treatment Pharmaceutical Companies Research Small Molecule 52

DrugBank

FEBRUARY 26, 2025

Developing Antimicrobial Peptides and Biomolecules In addition to traditional small-molecule antibiotics, researchers are exploring the potential of antimicrobial peptides (AMPs) and other biomolecules. These natural organisms are particular to their bacterial targets, minimizing collateral damage to the microbiome.

Therapies 52

Therapies Pharmaceutical Companies Pharmacokinetics Treatment 52

The Pharma Data

DECEMBER 27, 2020

XGEVA has also received conditional approval in China for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors and in patients with multiple myeloma (MM), which was not eligible for 2020 NRDL considerations as it was approved after the cutoff date. About Tislelizumab. R on macrophages.

Production 52

Production Therapies Drugs Treatment 52

The Pharma Data

DECEMBER 10, 2020

The most common adverse events of BNT162b2 were transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days. Rates of serious adverse events were similar between vaccine and placebo groups (0.6% kg/m2); and 21% had at least one underlying comorbidity.

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

Codon

APRIL 2, 2023

Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. Read A really simple way to isolate AAVs, which are a type of virus often used to deliver gene therapies into cells. Read Small-molecule aptamer for regulating RNA functions in mammalian cells and animals.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

MARCH 11, 2021

This clearly demonstrates the power of the COVID-19 vaccine to fight this virus and encourages us to continue even more intensively with our vaccination campaign. Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS at [link] or by calling 1-800-822-7967.

Vaccine 52

Vaccine Clinical Trials Hospitals Licensing 52

The Pharma Data

JANUARY 18, 2021

The fireside chat will be available for 90+ days following the event at: [link] 5 69. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. A live webcast of this presentation will be available for registered participants at: [link]. About Sorrento Therapeutics, Inc.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

JANUARY 13, 2021

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

BioPharma Drive: Drug Pricing

JUNE 23, 2025

Published June 23, 2025 Delilah Alvarado Staff Reporter post share post print email license A micrograph image of influenza A virus. Influenza A virus" [Micrograph]. The drug, an antiviral that combines a small molecule with a protein fragment, met its main and secondary goals in a Phase 2b trial. Retrieved from Flickr.

Drugs 264

Drugs Virus Therapies FDA 264

The Pharma Data

SEPTEMBER 15, 2020

An update on Pfizer’s potential first-in-class maternal vaccine candidate for the prevention of respiratory syncytial virus (RSVpreF). No Serious Adverse Events (SAE) were observed among the nine additional boys who were treated using a modified immunomodulatory regimen and monitoring regimen. BNT162 mRNA-based Vaccine Program.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

JUNE 24, 2021

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer?BioNTech Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS online at [link]. BioNTech COVID-19 Vaccine.

Government 52

Government Vaccine Clinical Trials Licensing 52

The Pharma Data

APRIL 27, 2021

Sanofi expects 2021 business EPS ( 1) to grow high single digit (2) at CER, barring unforeseen major adverse events. 3) within 24 hours of either the TIA or IS event. On February 23, 2021 Sanofi entered into a collaboration with Sirion to innovate gene therapy treatment with improved adeno-associated virus capsids.

Vaccine 52

Vaccine Production FDA Disease 52

Codon

DECEMBER 12, 2024

A mirrored organism would use right-handed molecules everywhere a naturally-occurring organism uses left-handed ones, and vice versa. Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine.

RNA 104

RNA DNA Vaccine Virus 104

Codon

MAY 30, 2023

Read *An engineered influenza virus to deliver antigens for lung cancer vaccination. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Read Programming inactive RNA-binding small molecules into bioactive degraders. Nature Chemical Biology. Nature Biotechnology.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

Read *An engineered influenza virus to deliver antigens for lung cancer vaccination. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Read Programming inactive RNA-binding small molecules into bioactive degraders. Nature Chemical Biology. Nature Biotechnology.

DNA 52

DNA RNA Engineering Vaccine 52

The Pharma Data

DECEMBER 20, 2020

It is an optimized, non-chemically modified mRNA that codes for the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus. Auxora is a potent and selective small molecule CRAC channel inhibitor that prevents CRAC channel overactivation. AstroRx is an off-the-shelf, clinical-grade, astrocyte cell product.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

The Pharma Data

OCTOBER 25, 2020

The UK government’s COVID-19 Vaccine Taskforce and a contract research company called Open Orphan announced a $13 million (£10 million) plan to test investigational COVID-19 vaccines in volunteers who are then intentionally exposed to SARS-CoV-2, the virus that causes COVID-19. No serious adverse events were observed.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. These statements are based on current expectations of future events.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. These statements are based on current expectations of future events.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

APRIL 27, 2021

We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe, as the deadly virus continues to wreak havoc across the continent.” IMPORTANT SAFETY INFORMATION: Events of anaphylaxis have been reported. A slightly lower frequency of reactogenicity events was associated with greater age.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

JULY 21, 2021

Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Viral reactivation including herpes virus and hepatitis B reactivation have been reported. Many of these events were serious and some resulted in death. About Abrocitinib. MALIGNANCIES. Avoid XELJANZ in patients at risk.

FDA 52

FDA Clinical Trials Treatment Therapies 52

The Pharma Data

APRIL 7, 2021

Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Viral reactivation including herpes virus and hepatitis B reactivation have been reported. Many of these events were serious and some resulted in death. About Abrocitinib. MALIGNANCIES. Avoid XELJANZ in patients at risk.

Treatment 52

Treatment Clinical Trials Therapies Vaccine 52

Codon

MAY 29, 2025

While small-molecule drugs continue to play a critical role in modern medicine, we are witnessing a shift toward the increasing development of amino acid-based therapeutics. These abilities are precisely what make them promising as potential therapies, particularly as we find ways to enhance their safety profiles.

Drugs 103

Drugs DNA RNA Laboratories 103

New Drug Approvals

MAY 5, 2025

Formula C 22 H 26 FN 3 O 2 7BS8743F3E CINSEBRUTINIB is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication. In addition, BTK is expressed in HIV infected T-cells and treatment with BTK inhibitors sensitizes infected cells to apoptotic death and results in decreased virus production.

Treatment 57

Treatment Disease Immune Response Clinical Trials 57